The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability
- PMID: 2917275
- DOI: 10.1093/brain/112.1.133
The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability
Abstract
The outcome of multiple sclerosis (MS), assessed according to the Kurtzke Disability Status Scale (DSS), was reviewed in 1,099 consecutive patients followed in London, Canada, between 1972 and 1984. A geographically based subgroup of 196 patients representing 90% of Middlesex County MS patients as well as a group of 197 patients seen from onset of disease were separately analysed. The clinical course was progressive from onset in 33% of the total population and in 28% of the Middlesex County subgroup. Of those with duration of 6-10 yrs, 30-40% with initially remitting disease developed progressive MS. The cross-sectional distribution of disability was bimodal with peaks at DSS 1 (no disability) and DSS 6 (assistance required for walking). Actuarial analysis showed that the median time to reach DSS 6 from onset of MS was 14.97 +/- 0.31 yrs in the total population and 9.42 +/- 0.44 yrs in the "seen from onset' subgroup. Survival was minimally altered; 87% of patients followed up to 40 yrs were still alive, although ascertainment of cases with this duration of MS was incomplete. Data describing the rate at which disability develops after the onset of a progressive phase of MS are also presented. The implications of these data in planning and interpretation of clinical therapeutic trials are discussed.
Similar articles
-
The natural history of multiple sclerosis: a geographically based study. 2. Predictive value of the early clinical course.Brain. 1989 Dec;112 ( Pt 6):1419-28. doi: 10.1093/brain/112.6.1419. Brain. 1989. PMID: 2597989
-
The natural history of multiple sclerosis: a geographically based study. 5. The clinical features and natural history of primary progressive multiple sclerosis.Brain. 1999 Apr;122 ( Pt 4):625-39. doi: 10.1093/brain/122.4.625. Brain. 1999. PMID: 10219776
-
The natural history of multiple sclerosis: a regional study with some longitudinal data.J Neurol Neurosurg Psychiatry. 1992 May;55(5):341-6. doi: 10.1136/jnnp.55.5.341. J Neurol Neurosurg Psychiatry. 1992. PMID: 1602305 Free PMC article.
-
Mitoxantrone: a review of its use in multiple sclerosis.CNS Drugs. 2004;18(6):379-96. doi: 10.2165/00023210-200418060-00010. CNS Drugs. 2004. PMID: 15089110 Review.
-
The natural history of multiple sclerosis.Can J Neurol Sci. 1987 Aug;14(3):255-61. doi: 10.1017/s0317167100026573. Can J Neurol Sci. 1987. PMID: 3311324 Review.
Cited by
-
Onset of progressive phase is an age-dependent clinical milestone in multiple sclerosis.Mult Scler. 2013 Feb;19(2):188-98. doi: 10.1177/1352458512451510. Epub 2012 Jun 26. Mult Scler. 2013. PMID: 22736750 Free PMC article.
-
Therapeutic adherence and coping strategies in patients with multiple sclerosis: An observational study.Medicine (Baltimore). 2019 Jul;98(29):e16532. doi: 10.1097/MD.0000000000016532. Medicine (Baltimore). 2019. PMID: 31335734 Free PMC article.
-
Long-term treatment of multiple sclerosis with interferon-beta may be cost effective.Pharmacoeconomics. 2000 Jul;18(1):45-53. doi: 10.2165/00019053-200018010-00005. Pharmacoeconomics. 2000. PMID: 11010603 Review.
-
Assessment of Multiple Sclerosis Patients' Knowledge and Behavioral Practice Regarding COVID-19 in Saudi Arabia.Cureus. 2022 Dec 21;14(12):e32781. doi: 10.7759/cureus.32781. eCollection 2022 Dec. Cureus. 2022. PMID: 36686104 Free PMC article.
-
Treatment of multiple sclerosis with interferon beta: an appraisal of cost-effectiveness and quality of life.J Neurol Neurosurg Psychiatry. 2000 Feb;68(2):144-9. doi: 10.1136/jnnp.68.2.144. J Neurol Neurosurg Psychiatry. 2000. PMID: 10644777 Free PMC article.
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical